Immediate versus gradual TocilizuMab discontinuAtion in GIant Cell Arteritis: protocol of the multicentre randomised open-label MAGICA trial
Introduction Giant cell arteritis (GCA) is a large-vessel vasculitis occurring in people aged over 50 years. Recent studies have shown that tocilizumab (TCZ), an anti-IL-6 receptor monoclonal antibody, is remarkably effective in treating GCA and allows significant dose sparing of glucocorticoids. Ho...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMJ Publishing Group
2025-10-01
|
| سلاسل: | BMJ Open |
| الوصول للمادة أونلاين: | https://bmjopen.bmj.com/content/15/10/e108115.full |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
